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Figure 1

Figure 2

MRI Brain 11/25/2005 – No tentorial
mass lesion

MRI Brain Axial Image with Gadolinium
on 6/1/2010 – showing bilateral tentorial and posterior falx mass lesion

First described in 1969, RDD is characterized by accumulation of histiocytes
exhibiting emperipolesis in lymph nodes,
in the head and neck or in extranodal
sites. Extranodal sites include the CNS,
skin, soft tissue and gastrointestinal tract.
The clinical presentation is typically
painless cervical lymphadenopathy with
leukocytosis and a fever. 5 The etiology
of RDD is unknown.6 RDD with CNS
involvement is rare and approximately
210 cases have been reported. CNS
involvement typically lacks extracranial lymphadenopathy and resembles
meningioma radiologically and clinically.1 Select cases have demonstrated
a combined presentation of ECD and
RDD. 2
In this report we describe a rare case
presenting with headache and with
clinically and pathologically overlapping
features of RDD and ECD. We describe
treatment and complications and review
the existing literature regarding diagnosis
and treatment for these rare conditions.

Introduction

Case Report

The histiocytoses are a group of clinically diverse diseases distinguished from one
another based on the specific immunophenotype of the lesional cells, implying derivation from the same precursor cell. Langerhans cell histiocytoses (LCH) diseases
stem from abnormal dendritic cell lineages, while the non-Langerhans cell histiocytoses (non-LCH) are usually derived from an abnormal monocyte/macrophage cell
line.1 Non-LCH with central nervous system (CNS) involvement is predictive of poor
outcome. Histopathology is used to make a diagnosis of non-LCH. Immunohistochemistry and the clinical setting are used to differentiate between the various subtypes of
non-LCH.1 The non-LCH can be divided into cutaneous non-LCH, cutaneous with a
major systemic component, and systemic non-LCH.1 Erdheim-Chester disease (ECD)
and Rosai-Dorfman disease (RDD) are systemic non-LCH diseases.

The patient is a 46-year-old gentleman
from Mexico who was initially admitted
to the Neurology service at Jefferson
Hospital for Neuroscience in November
2005 with headache, vertigo, nausea and
vomiting and was found to have bilateral
vertebral artery dissection with proximal
basilar artery thrombosis (MRI Picture,
Figure 1). He was started on anticoagulation and discharged home. In June 2010
he presented to the neurosurgery office
with worsening headaches and a MRI
of the brain showed bilateral tentorial
and posterior falcine mass suggestive
of meningioma (MRI Picture, Figure 2).
The mass was surrounding the incisura.

First described in 1930, ECD is characterized by xanthogranulomatous accumulations.
The extent of infiltration is heterogeneous and can include skin, bones, lungs, kidneys,
and the CNS. Approximately 500 cases have been reported so far. 2 The majority of
ECD patients harbor an activating mutation of the proto-oncogene BRAF, namely
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BRAF-V600E. 3 Recent studies indicate
CNS involvement as a predictor of
highest mortality among ECD patients.4
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Figure 3
MRI Brain Axial Image with Gadolinium
7/25/2011- showing progression of b/l
tentorial and posterior falx mass lesion
MRI Brain Sagittal Image with Gadolinium 7/25/2011 – showing sinonasal
and sellar mass lesions

He also had an enhancing lesion in the
ethmoid sinus. He was recommended to
have a procedure for tissue diagnosis but
he failed to do so and was lost to follow up.
In July 2011 he represented to the
Jefferson Hospital ER with worsening
symptoms and new onset diabetes insipidus. MRI brain, MR angiogram and CT
sinus showed progression of the tentorial
mass and a new sellar mass in the region
of the pituitary gland and extensive sinonasal soft tissue mass extending into the
right orbit (MRI Picture, Figure 3). On
7/28/2011 he underwent endoscopic
transnasal transsphenoidal resection of
the sinonasal and sellar mass. He also
had an enhancing lesion in the ethmoid
sinus. He was recommended to have a
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Path Slide 1
First operation A-E. A. Inflammatory infiltrate composed of lymphocytes, plasma cells,
and histiocytes (Hematoxylin and Eosin, 200X). B. High magnification (Hematoxylin
and Eosin, 1000X) demonstrates a typical Rosai-Dorfman histiocyte with neutrophils
and plasma cells undergoing emperipolesis (arrowed). C,D. The histiocytes are strongly
immunoreactive for CD163 (200X) and S-100 (200X) respectively. E. High magnfication
(1000X) confirms the presence of emperipolesis (arrowed) within S-100 immunoreactive
histiocytes. F. Second operation, sheets of foamy macrophages without emperipolesis
(H&E, 400X). mass lesions

procedure for tissue diagnosis but he
failed to do so and was lost to follow up.
The lesion consisted of an inflammatory
infiltrate composed of lymphocytes,
plasma cells and histiocytes (path slide
1A). High magnification images demonstrated intact inflammatory cells within
the cytoplasm of many of the large
histiocytes (path slide 1B). This phenomenon, known as emperipolesis, is

characteristic of Rosai-Dorfman Disease.
These histiocytes were immunohistochemically positive for macrophage
markers CD68 and CD163 (path slide 1C)
as well as S-100 (path slide 1D, E), but
were negative for CD1a. This immunophenotype is typical of Rosai-Dorfman
histiocytes. In contrast, macrophages
and Erdheim-Chester histiocytes are
immunoreactive for CD68 and CD163
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During the same hospitalization he
developed left ureteroplevic junction obstruction and hydronephrosis
requiring stent placement.
He was discharged to rehab with
outpatient follow up. From 8/29/2011
to 9/14/2011 he completed radiation
therapy of 24 Gy in 12 fractions to the
paranasal sinuses and whole brain. In
December 2011 he was started on interferon alpha and had vast improvement of
his symptoms.

Figure 4

Figure 5

Pre Op MRI Brain Axial Image with Gadolinium 5/19/2012 – showing infratentorial
and supratentorial mass

Post Op MRI Brian Axial Image with
Gadolinium 5/26/2012 – showing gross
total resection

In May 2012 he was readmitted with
worsening headache and vision, on exam
he had left homonymous hemianopia.
MRI of the brain showed progression
of the tentorial mass, compressing the
occipital lobes bilaterally (MRI Picture,
Figure 4). He was taken to the operating
room and underwent an occipital/suboccipital craniotomy. A near total resection
of a solid avascular mass arising from
the tentorium was performed using a
combined supratentorial and infratentorial approach. Post-operative MRI of the
brain confirmed minimal residual on the
right aspect of the tentorium and posterior falx (MRI Picture Figure 5).
Pathology from this resection was characteristic of ECD, revealing large numbers
of foamy macrophages (path slide 1F) with
foci of necrosis and cholesterol clefts.
There was no evidence of emperipolesis
and these macrophages/histiocytes were
immunoreactive for CD68 and CD163,
but negative for S-100 and CD1a. This
immunophenotype is distinctly different
from the original resection, and with the
patient’s clinical picture and multisystem
involvement, points towards ECD. His
headaches improved, and he was subsequently discharged home.

Figure 6
CT head without contrast 9/26/2014- showing hydrocephalus
CT head without contrast 10/04/2014 – post op after VP shunt showing resolution of
hydrocephalus

but negative for S-100 and CD1a. Langerhan’s cell histiocytes are immunoreactive
for CD68, CD163, S-100, and CD1a. While
the resection’s pathology was consistent
with RDD, the chest, abdomen and pelvis
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done to rule out systemic disease
showed pulmonary interstitial thickening with fibrotic changes and the
perinephric fat stranding consistent
with ECD.

On June 12, 2012 he was admitted with
an episode of unresponsiveness and
was found to have a MRSA pneumonia
with presumed sepsis. In the course of
this hospitalization he was found unresponsive and in ventricular fibrillation.
A cardiac catheterization revealed nonocclusive coronary artery disease and
he underwent implantable cardioverterdefibrillator placement on 6/27/12.
By June 2013 his diabetes insipidus had
resolved and overall he was feeling much
better. He was lost to follow up since he
returned to Mexico, however he presented
in September 2014 with headache, gait
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are rare. Headaches and seizures are
common as well as other neurological
symptoms depending on the location of
the lesion; constitutional symptoms are
usually absent.5

ataxia (right greater than left cerebellar
dysmetria), left homonymous hemianopsia
and on non-contrast head CT was found
to have progressive communicating hydrocephalus. On 9/29/2014 he underwent a
right ventriculoperitoneal shunt placement
for relief (CT head pre and post VP shunt,
Figure 6). CT head with contrast showed
some recurrence of the tentorial mass (CT
head with contrast, Figure 7) He recovered
well enough and was discharged to rehabilitation unit.

To make a diagnosis of RDD, an excisional
biopsy should be performed for immunohistochemical and morphological
analyses. 5 The hallmark of RDD cells is
emperipolesis or the nondestructive
phagocytosis of lymphocytes or erythrocytes.5 Cells will be positive for CD68
(KP-1), CD163, and S100 and are negative
for CD1a.5

Discussion
ECD is a rare systemic non-LCH involving
xanthogranulomatous infiltration of
tissues by foamy histiocytes (lipid-laded
macrophages) surrounded by fibrosis. 2 It
is typically diagnosed in the fifth decade
of life, with a mean age of 55, and is more
prevalent in males than females. ECD is
considered to be both a neoplastic and
inflammatory disorder, as the disease associates with a specific oncogenic alteration
in the form of the BRAFV600E mutation,
as well as a characteristic inflammatory
pattern of cytokines and chemokines.7
Although it is a clinically heterogeneous
disease involving several organ systems,
ECD patients most commonly present
with bilateral osteosclerosis of long bones
of the upper and lower extremities on CT
scans.8 Other associated systemic manifestations include pseudotumor of the right
heart, pericardial fibrosis, “hairy kidney”
due to infiltration into perinephric soft
tissue, exophthalmos, pulmonary fibrosis,
and CNS involvement. 2,9 Less than 50% of
patients with proven ECD have neurologic
involvement.8 The most common neurological symptoms are diabetes insipidus
and cerebellar issues, both of which are
part of our patient’s history. 10 Lesions in
the CNS have been specifically identified in
the hypothalamic-pituitary axis, cavernous
sinus, orbits, paranasal sinuses, brainstem,
and vertebral column.8 The prognosis for
patients with ECD is variable and depends
on the extent of disease. 2,8 Renal failure,
cardiomyopathy, and respiratory failure
are the most common causes of death
in patients with ECD.8 59% of patients
succumb to ECD after a mean follow-up
of 32 months.1 1
The definitive diagnosis for ECD can only
be made via histopathology analysis and
immunohistochemistry, with the presence
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Figure 7
CT head with contrast 10/09/2014 –
showing recurrence of infratentorial
and supratentorial mass lesions

of infiltrating foamy, lipid-laden histiocytes, characteristic multinucleated
Touton-type giant cells, and fibrosis. 2,10
Cells are positive for CD68 and negative
for CD1a.12
RDD is a nonmalignant non-LCH histiocytosis in which histiocytes infiltrate
lymph nodes or extranodal tissues. RDD is
typically diagnosed in the second or third
decade of life and is more prevalent in
African American individuals and in males
compared to females. 5,13 Patients with
RDD classically present with symptoms
of fever and massive, nonpainful cervical
lymphadenopathy. Some patients experience night sweats and weight loss as well
as painless maculopapular eruptions.5,14
Osteolytic bone lesions are rare in RDD,
unlike in patients with Langerhans cell
histiocytosis.15 20% of patients with RDD
have spontaneous regression without
treatment. 16 In patients without treatment, 70% will experience a relapsing and
remitting course.16
Common sites for extranodal infiltration
include the CNS, skin, orbit and eyelid,
upper respiratory tract, and the gastrointestinal tract; some reports suggest
extranodal involvement may occur in
up to 40% of cases. 5 CNS involvement
of RDD is commonly with dura-based,
extra-axial involvement of the cranium;
spinal cord and intracerebral disease

It is not uncommon for patients to present
with both ECD and another form of LCH
or non-LCH, as evidenced in 15% of 101
patients by Haroche et al. 2 Our patient
presented in this case report falls into
this category, concurrently expressing
two systemic forms, ECD and RDD.
Treatment, both surgical and nonsurgical, is similar for these two non-LCH
diseases. For asymptomatic patients, it is
recommended to observe, with close
following of the disease for progression.
However, for symptomatic patients with
localized lesions, particularly in the CNS,
surgical resection and/or radiotherapy
is the treatment of choice. In a study
involving 10 RDD patients with CNS
involvement, 7 of them achieved remission at follow-up after surgical resection
of the lesions.17
Interferon alpha (IFNα) therapy is the most
studied,7 and Haroche et al. recommends
IFNα therapy as the initial treatment for
patients with symptomatic ECD. In their
survival analysis of 53 patients, treatment
with IFNα was an independent predictor
of survival. 2 High dose IFNα is most effective for CNS and cardiac involvement as
Haroche et al. reported symptoms did not
resolve in response to low dose IFNα. Side
effects of IFNα can be intolerable and
include fatigue and depression. 2 Other
non-surgical treatments currently being
investigated for ECD patients with a more
disseminated disease including: methotrexate18, canakinumab19, vemurafenib
(20), and interleukin-1 targeting drugs/
glucocorticoids. 21 Vemurafenib, a BRAF
inhibitor, has recently been utilized as
an effective treatment for ECD patients
harboring the BRAFV600E mutation with
severe and refractory ECD, resulting in
significant clinical improvement. 2,7
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Patients with RDD experiencing symptoms have nonsurgical treatment options
such as radiotherapy, steroids or chemotherapy agents including vinca alkaloids
and anthracyclines. 5 ECD and RDD are
rare diseases and treatment options
need to be studied further in randomized
controlled trials in order to determine the
best treatment for these patients.
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